Pitié-Salpêtrière Hospital
Paris, 75013, France
Location contact
Maxime PATOUT PATOUT, MD
CONTACT
Maxime PATOUT PATOUT, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06997146
The CCHS study is a prospective, open-label, monocentric, interventional study with diagnostic and prognostic objectives, conducted in two phases. The first phase aims to identify biomarkers and dysregulated biological pathways in patients with Congenital Central Hypoventilation Syndrome (CCHS) by analyzing blood and urine samples of patients and matched healthy controls collected at multiple timepoints during sleep and wakefulness. In the second phase, these candidate biomarkers and pathways will be validated in a larger cohort of patients and matched healthy controls using targeted assays such as RT-PCR and mass spectrometry-based metabolomic analysis. The primary objective is to uncover molecular signatures that could explain disease mechanisms, while the secondary objective is to explore potential biomarkers and treatment targets that can improve spontaneous breathing and CO₂ responsiveness in CCHS patients. The underlying hypothesis is that multi-omics profiling of blood and urine can reveal actionable insights into the pathophysiology of CCHS and support the development of targeted interventions.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Paris, 75013, France
Maxime PATOUT PATOUT, MD
CONTACT
Maxime PATOUT PATOUT, MD
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
CCHS patients :
Control group :
Exclusion criteria
CCHS patients :
Control group :
Collection of 10 mL of blood (separated into aliquots for RNA-seq and metabolomic analysis) and 5 mL of urine from participants at various timepoints during sleep and wakefulness. These samples will be used to analyze biomarkers and dysregulated biological pathways related to CCHS.
Participants will undergo polysomnography to assess sleep patterns and respiratory function during sleep. This will help evaluate any sleep-related breathing abnormalities in patients with CCHS and compare them with healthy controls.
spirometry, ventilatory response to CO2
Time frame: Day 0 to Month 37
In the first phase of this study, candidate CCHS-related biomarkers and dysregulated pathways will be identified based on the analysis of the generated omics data. Candidate transcripts and metabolites that meet the criteria listed below will be further tested in the second targeted validation phase in an additional larger cohort of patients and matched controls. These will be sampled and analysed by specific tests (RT PCR or targeted metabolic analysis), that are relevant for each of the candidate transcripts and metabolites.
The following criteria will be employed in the analyses of both phases:
Time frame: Day 0 to Month 37
New CCHS prognostic biomarkers will be identified by analyzing significant correlations between biomarker levels (such as RNA, metabolites, etc.) and performance on breathing tests in CCHS patients.
Time frame: Day 0 to Month 37
The evaluation criteria for the identification and prioritization of new candidate treatment targets would include finding a solid scientific rational and defined and prioritized according to their parameters regarding pharmacodynamic-pharmacokinetic (PK/PD), ability to cross the blood brain barrier, drug developmental phase, regulatory status, intellectual property condition, and overall risk-benefit balance.
Time frame: Day 0 to Month 37
Relevant repurposed drugs/supplements will be defined and prioritized according to their parameters regarding pharmacodynamic-pharmacokinetic (PK/PD), ability to cross the blood brain barrier, drug developmental phase, regulatory status, intellectual property condition, and overall risk-benefit balance.
Contact information is provided by the study sponsor or research team.
Alexis PEREZ CALOC Clinical project manager
CONTACT
Maxime PATOUT PATOUT, MD
CONTACT
Assistance Publique - Hôpitaux de Paris
Other
Acronym: CCHSBiomarkers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06337149
Apnea, Congenital Central Hypoventilation Syndrome (CCHS)
Paris, France
View Trial DetailsNCT07081464
Apnea, Cognition Disorders
Paris, Ap-hp / DRCI, France
View Trial DetailsNCT06554275
Congenital Central Hypoventilation Syndrome, Congenital central hypoventilation syndrome
Chicago, Illinois, United States
View Trial DetailsNCT03568669
Apnea, CCHS
Los Angeles, California, United States
View Trial Details